Articles related to KIDNEY DISEASE

The US Food and Drug Administration (FDA) has said “no” to Akebia Therapeutics’ drug application for vadadustat, a therapy to treat anemia due to chronic kidney disease. Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. The FDA cited safety concerns as the main reason for it rejecting the application.

In contradistinction to recent reports that showed increased risk of death and no clinical benefit with escalation of allopurinol for progressive CKD, this 5-year population-based review found no increased mortality risk in escalating allopurinol dose and achieving target serum urate levels.

Test your knowledge on this case study from JAMA Oncology! Full text available with registration, or you can access the Clinical Challenge from your institution. Good luck!

MDCalc.com offers this helpful tool, which calculates creatinine clearance (CrCl) according to the Cockcroft-Gault equation. The tool also allows height input, which analyzes BMI and provides a modified estimate and range.